Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018

BACKGROUND: TB is the leading cause of mortality among people living with HIV (PLHIV), for whom isoniazid preventive therapy (IPT) has a proven mortality benefit. Despite WHO recommendations, countries have been slow in scaling up IPT. This study describes processes, challenges, solutions, outcomes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The international journal of tuberculosis and lung disease 2021-05, Vol.25 (5), p.367-372
Hauptverfasser:	Weyenga, H., Karanja, M., Onyango, E., Katana, A. K., Ng´ang´a, L. W., Sirengo, M., Ondondo, R. O., Wambugu, C., Waruingi, R. N., Muthee, R. W., Masini, E., Ngugi, E. W., Shah, N. S., Pathmanathan, I., Maloney, S., De Cock, K. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use HIV HIV Infections - drug therapy HIV Infections - epidemiology HIV-positive Human immunodeficiency virus Humans Isoniazid Isoniazid - therapeutic use Kenya - epidemiology Leadership Mortality Patients Prevention Scaling up Tuberculosis Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!